Modeling signal transduction in normal and cancer cells using complex adaptive systems

Medical Hypotheses

Volumn 48, Issue 2, 1997, Pages 111-123

  Schwab, E D ^a   Pienta, K J ^a,b  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b Division of Hematology Oncology 3216 Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTATION; ANIMAL; ARTICLE; BIOLOGICAL MODEL; CARCINOGENESIS; CELL; CELL DIFFERENTIATION; CELL FUNCTION; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; HUMAN; HYPOTHESIS; NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; REFERENCE VALUE; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0031081389     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(97)90278-4     Document Type: Article

References (55)

1. Schwab E D, Pienta K J. Cancer as a complex adaptive system. Med Hypotheses 1996; 47: 235-242.
2. Lewin R. Complexity: Life at the Edge of Chaos. New York: Macmillan, 1992.
3. Gleick J. Chaos: Making a New Science. New York: Penguin, 1987: 9-32, 119-154.
4. Marimon R, McGratten E, Sargent T J. Money as a medium of exchange in an economy with artificially intelligent agents. J Econ Dynamics Cont 1990; 14: 329-373.
5. Perelson A S. Two theoretical problems in immunology: AIDS and epitopes. In: Cowan G A, Pines D, Meltzer D, eds. Complexity: Metaphors, Models and Reality. Reading: Addison-Wesley, 1994.
6. Holland J. Hidden Order: How Adaptation Builds Complexity. New York: Addison-Wesley, 1995: 1-40.
7. Bos J L. ras oncogenes in human cancer: a review. Canc Res 1989; 49: 4682-4689.
8. Mulcahy L S, Smith M R, Stacy D W. Requirements for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature 1985; 313: 241-243.
9. Feramisco J R, Clarc R, Wong G, Arheim N, Milley R, McCormick F. Transient reversion of ras oncogene-induced cell transformation by antibodies specific for amino acid 12 of ras protein. Nature 1985; 314: 639-642.
10. Satoh T, Kaziro Y. Ras in signal transduction. Canc Biol 1992; 3: 169-177.
11. Spandidos D A, Anderson M L M. A study of mechanisms of carcinogenesis by gene transfer of oncogenes into mammalian cells. Mutat Res 1987; 185: 271-291.
12. Gibbs J B, Marshall M S, Scolnick E M, Dixon R A F, Vogel U S. Modulation of guanine nucleotides bound to ras in NIH3T3 cells by oncogenes, growth factors, and the GTPase activating protein (GAP). J Biol Chem 1990; 265: 20437-20442.
13. Satoh T, Endo M, Nakafuku M, Akiyama T, Yamamoto T, Kaziro Y. Accumulation of p21 ras GTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activity. Proc Natl Acad Sci USA 1990; 87: 7926-7929.
14. Howe L R, Leevers S J, Gomez N, Nakielny S, Cohen P. Activation of the MAP kinase pathway by the protein kinase raf. Cell 1992; 71: 335-342.
15. Hall A. Ras-related GTPases and the cytoskeleton. Mol Biol Cell 1992; 3: 475-479.
16. Downward J. Rac and rho in tune. Nature 1992; 359: 273-274.
17. Lowy D R, Willumsen B M. Function and regulation of ras. Annu Rev Biochem 1993; 62: 851-891.
18. Pawson T, Gish G D. SH2 and SH3 domains: from structure to function. Cell 1992; 71: 359-362.
19. 2+-dependent translocation domain with homology to PKC and GAP. Cell 1991; 65: 1043-1051.
20. Duchesne M, Schweighoffer F, Parker F et al. Identification of the SH3 domain of GAP as an essential sequence for Ras-GAP-mediated signaling. Science 1993; 259: 525-528.
21. Bollag G, McCormick F. NF is enough of GAP. Nature 1992; 356: 663-664.
22. Willumsen B M, Christensen A, Hubbert N L, Papageorge A G, Lowy D R. The p21-ras C-terminus is required for transformation and membrane association. Nature 1984; 310: 583-586.
23. Wood K W, Sarnecki C, Roberts, T M, Blemis J. ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK. Cell 1992; 68: 1041-1050.
24. Ridley A J, Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992; 70: 389-399.
25. Torres R, Schreiber-Agus N, Morgenbesser S, DePinho R. Myc and Max: a putative transcriptional complex in search of a cellular target. Curr Opin Cell Biol 1992; 4: 468-474.
26. Spencer C A, Groudine M. Control of c-myc regulation in normal and neoplastic cells. Adv Canc Res 1991; 56: 1-48.
27. Kelly K, Cochran B H, Stiles C D, Leder P. Cell specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 1983; 35: 603-610.
28. Bravo R. Growth factor-responsive genes in fibroblasts. Cell Growth Diff 1990; 1: 305-309.
29. Dean M, Levine R A, Ran W, Kindy M S, Sonenshein G E, Campisi J. Regulation of c-myc transcription and mRNA abundance by serum growth factors and cell contact. J Cell Biochem 1986; 261: 9161-9166.
30. Waters C, Littlewood T, Hancock D, Moore J, Evan G. c-myc protein expression in untransformed fibroblasts. Oncogene 1991; 6: 101-109.
31. Quarmby V, Beekman W, Wilson E, French F. Androgen regulation of c-myc messenger ribonucleic acid levels in rat ventral prostate. Mol Endocrinol 1987; 1: 865-874.
32. Kyprianou N, English H F, Davidson N E, Isaacs J T. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Canc Res 1991; 51: 162-166.
33. Evan G I, Litt dewood T D. The role of c-myc in cell growth. Curr Opin Genet Dev 1993; 3: 44-49.
34. Blackwell T K, Kretzner L, Blackwood E M, Eisenman R N, Weintraub H. Sequence-specific DNA binding by the c-myc protein. Science 1990; 250: 1149-1151.
35. Amati B, Dalton S, Brooks M, Littlewood T, Evan G, Land H. Transcriptional activation by c-Myc oncoprotein in yeast requires interaction with Max. Nature 1992; 359: 423-426.
36. Littlewood T, Amati B, Land H, Evan G. Max and c-Myc/Max DNA binding activities in cell extracts. Oncogene 1992; 7: 1783-1792.
37. Blackwood E M, Luscher B, Eisenman R N. Myc and Max associate in vivo. Genes Dev 1992; 6: 71-80.
38. Prochnowik E V, Kukowska J, Rodgers C. c-myc antisense transcripts accelerate differentiation and inhibit G1 progression in murine erythroleukemia cells. Mol Cell Biol 1988; 8: 3683-3695.
39. Hann S R, Thompson C B, Eisenman R N. c-myc oncogene protein synthesis is independent of cell cycle in human and avian cells. Nature 1985; 314: 366-369.
40. Wagner A J, Meyers C, Lamins L A, Hay N. c-Myc induces the expression and activity of ornithine decarboxylase. Cell Growth Diff 1993; 4: 879-883.
41. Tavtigian S V, Zabludoff S D, Wold B J. Cloning of mid-G1 serum response genes and identification of a subset regulated by conditional myc expression. Mol Biol Cell 1994; 5: 375-388.
42. Tabor C W, Tabor H. Polyamines. Annu Rev Biochem 1984; 53: 749-790.
43. Pegg A E. Recent advances in the biochemistry of polyamines in eukaryotes. J Biochem 1986; 234: 249-262.
44. Askew D, Ashmun R, Simmons B, Cleveland J. Constitutive c-myc expression in IL-3-dependent myeloid cell line suppresses cycle arrest and accelerates apoptosis. Oncogene 1991; 6: 1915-1922.
45. Land H, Parada L F, Weinberg R A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983; 304: 596-602.
46. Korsmeyer S J, Shutter J R, Veis D J, Merry D E, Oltvai Z N. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Canc Biol 1993; 4: 327-332.
47. Jacobson M, Raff M C. Programmed cell death and Bcl-2 protection in very low oxygen. Nature 1995; 374: 814-816.
48. Shimizu S, Eguchl Y, Kosaka H, Kamiike W, Masuda H, Tsujimoto Y. Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xL. Nature 1995; 374: 811-813.
49. Sentman C L, Shutter J R, Hockenberry D, Kanagawa O, Korsmeyer S J. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991; 67: 879-888.
50. White E. Life, death, and the pursuit of apoptosis. Genes Dev 1996; 10: 1-15.
51. Yin X-M, Oltvai Z N, Korsmeyer S J. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with bax. Nature 1994; 369: 321-323.
52. Chittenden T, Flemmington C, Houghton A B et al. A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. EMBO J 1995; in press.
53. Nguyen M, Millar D G, Yong V W, Korsmeyer S J, Shore G C. Targeting of bcl-2 to the mitochondrial outer membrane by a COOH-terminal signal anchor sequence. J Biol Chem 1993; 268: 25265-25268.
54. Oltvai Z, Milliman C, Korsmeyer S J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
55. Hockenberry D M. bcl-2, a novel regulator of cell death. BioEssays 1995; 17: 631-638.